Financial Results for the quarter ended June 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kimia Biosciences reported Q1 FY26 revenue from operations of ₹2,358.41 lakhs, up ~5.3% YoY from ₹2,239.93 lakhs. However, profit after tax fell sharply to ₹60.40 lakhs from ₹143.70 lakhs YoY, a drop of about 58%. EPS slipped to ₹0.13 from ₹0.30 in the same quarter last year. Finance costs jumped ~58% YoY to ₹174.71 lakhs, weighing on margins. The auditor (Neeraj Arora & Associates) issued an unmodified limited review report. The Board also approved a ₹2 crore unsecured loan at 8% p.a. and appointed Mr. Pradip Kumar Sharma as the new CFO. The Board also noted a BSE warning letter dated July 25, 2025 for not disclosing an AGM extension/ROC submission.
Margins compressed meaningfully due to sharply higher finance costs despite modest revenue growth, which is a negative signal for profitability. The BSE warning letter flags prior compliance lapses; shareholders should watch for any further regulatory action.